Illuminare Biotechnologies Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Employees
  • 5

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $4.5M

  • Investors
  • 5

Illuminare Biotechnologies General Information

Description

Developer of an intra-operative nerve visualization technology intended to reduce the risk of nerve damage. The company's technology binds specifically to myelin and illuminates to make nerves, fat, muscles, and blood vessels more visible, enabling surgeons with improved visibility during operations.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 325 Saint Marks Avenue
  • Brooklyn
  • New York, NY 11238
  • United States
+1 (609)
Primary Industry
Other Pharmaceuticals and Biotechnology
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 325 Saint Marks Avenue
  • Brooklyn
  • New York, NY 11238
  • United States
+1 (609)

Illuminare Biotechnologies Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Illuminare Biotechnologies Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series B) 07-May-2026 $4.5M Completed Clinical Trials - Phase 2
4. Secondary Transaction - Private 01-Jan-2026 Completed Clinical Trials - Phase 2
3. Later Stage VC (Series B) 15-May-2023 Completed Clinical Trials - Phase 1
2. Early Stage VC (Series A) 18-Aug-2017 $2.37M $2.37M Completed Stealth
1. Early Stage VC 10-Jun-2016 Completed Stealth
To view Illuminare Biotechnologies’s complete valuation and funding history, request access »

Illuminare Biotechnologies Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B-1
Series B-2
Series A 7,100,000 $0.000001 5% $0.38 $0.38 1x $0.38 11.24%
To view Illuminare Biotechnologies’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Illuminare Biotechnologies Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of an intra-operative nerve visualization technology intended to reduce the risk of nerve damage. The company'
Other Pharmaceuticals and Biotechnology
New York, NY
5 As of 2026

La Jolla, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Illuminare Biotechnologies Competitors (1)

One of Illuminare Biotechnologies’s competitors is Alume Biosciences, a Venture Capital-Backed company based in La Jolla, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Alume Biosciences Venture Capital-Backed La Jolla, CA
You’re viewing 1 of 1 competitors. Get the full list »

Illuminare Biotechnologies Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Illuminare Biotechnologies Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
Band of Angels Angel Group Minority
Livewire Mobile Corporation Minority
Three B Holdings Family Office Minority
Endo Investors Venture Capital Minority
Thylacine Capital Venture Capital Minority
To view Illuminare Biotechnologies’s complete investors history, request access »

Illuminare Biotechnologies FAQs

  • When was Illuminare Biotechnologies founded?

    Illuminare Biotechnologies was founded in 2016.

  • Where is Illuminare Biotechnologies headquartered?

    Illuminare Biotechnologies is headquartered in New York, NY.

  • What is the size of Illuminare Biotechnologies?

    Illuminare Biotechnologies has 5 total employees.

  • What industry is Illuminare Biotechnologies in?

    Illuminare Biotechnologies’s primary industry is Other Pharmaceuticals and Biotechnology.

  • Is Illuminare Biotechnologies a private or public company?

    Illuminare Biotechnologies is a Private company.

  • What is the current valuation of Illuminare Biotechnologies?

    The current valuation of Illuminare Biotechnologies is .

  • What is Illuminare Biotechnologies’s current revenue?

    The current revenue for Illuminare Biotechnologies is .

  • How much funding has Illuminare Biotechnologies raised over time?

    Illuminare Biotechnologies has raised $11M.

  • Who are Illuminare Biotechnologies’s investors?

    Band of Angels, Livewire Mobile, Three B Holdings, Endo Investors, and Thylacine Capital have invested in Illuminare Biotechnologies.

  • Who are Illuminare Biotechnologies’s competitors?

    Alume Biosciences is a competitor of Illuminare Biotechnologies.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process